DS-ALL patients have a higher rate of relapse and treatment-related
mortality. We describe a DS-ALL patient with late bone marrow relapse
who was treated per British ALL R3 reinduction chemotherapy. The patient
remained in remission for approximately two years after therapy was
discontinued due to severe systemic infections.